Thermo Fisher Scientific launched its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel, a customizable menu of 22 verified real-time PCR assays for identification of SARS-CoV-2 mutations, according to a news release.
The company said the assays – which are available for research use only – enable surveillance of variants that are causing COVID-19 infections in specific regions globally and allow laboratories to choose which mutations to track.
The TaqMan SARS-CoV-2 Mutation Panel is designed to be highly scalable, being able to run a few or hundreds of samples to identify one or many mutations. The panel provides laboratories with the ability to meet various levels of testing need with real-time PCR instruments they already use, the company said.
The TaqMan SARS-CoV-2 Mutation Panel provides results in about an hour and is based on gold standard TaqMan SNP genotyping assay technology, which can help to detect and distinguish mutations efficiently.
